<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20187">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02136511</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-312-1325</org_study_id>
    <secondary_id>2013-005343-82</secondary_id>
    <nct_id>NCT02136511</nct_id>
  </id_info>
  <brief_title>Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia</brief_title>
  <official_title>An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated
      chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible
      for other Gilead-sponsored studies.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib 150 mg tablet administered orally twice daily</description>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously starting at 375 mg/m^2 at Week 0 and continuing with a dose of 500 mg/m^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.</description>
    <other_name>Rituxan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age with a diagnosis of B-cell CLL established according
             to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and
             documented within medical records

          2. CLL that warrants treatment (consistent with accepted IWCLL criteria for initiation
             of therapy)

          3. Prior treatment for CLL comprising any of the following:

               1. Prior treatment with ≥ 1 regimen containing a therapeutic anti-CD20 antibody or

               2. Prior treatment with ≥ 2 regimens containing ≥ 1 cytotoxic agent

          4. CLL progression &lt; 24 months since the completion of the last prior therapy for CLL

          5. Appropriate for noncytotoxic-containing therapy based on the presence of any of the
             following factors:

               1. Grade ≥ 3 neutropenia or thrombocytopenia attributable to cumulative
                  myelotoxicity from prior administration of cytotoxic agents (as documented by
                  bone marrow biopsy obtained since last prior therapy), or

               2. Estimated creatinine clearance &lt; 60 mL/min (as determined by the Cockcroft-Gault
                  method), or

               3. A Cumulative Illness Rating Scale (CIRS) score of &gt; 6

          6. A negative serum pregnancy test for female subjects of childbearing potential

          7. Male and female subjects of childbearing potential who engage in heterosexual
             intercourse must agree to use protocol-specified method(s) of contraception.

          8. Lactating females must agree to discontinue nursing before the study drug is
             administered.

          9. Evidence of a personally signed informed consent

        Exclusion Criteria:

          1. Known hypersensitivity to the idelalisib, its metabolites, or formulation
             excipient(s)

          2. Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          3. Known myelodysplastic syndrome

          4. Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             randomization

          5. Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active
             hepatitis B (HBV), alcoholic liver disease, nonalcoholic steatohepatitis, primary
             biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of
             the liver, or portal hypertension

          6. Ongoing drug-induced pneumonitis

          7. Ongoing inflammatory bowel disease

          8. History of anaphylaxis in association with previous administration of monoclonal
             antibodies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Jahn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sissy Peterman</last_name>
    <phone>206-832-2015</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego - Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0820</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pureza Vallar</last_name>
      <phone>858-822-7954</phone>
      <email>pvallar@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Kipps</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sampada Apte</last_name>
      <phone>202-784-2512</phone>
      <email>ska38@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Cheson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amanda Hutchison-Rzepka</last_name>
      <phone>404-778-3935</phone>
      <email>ahutch7@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Leonard Heffner Jr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Larsen</last_name>
      <phone>312-695-1377</phone>
      <email>daniel.larsen@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Shuo Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Renee Lomelino</last_name>
      <phone>551-996-5903</phone>
      <email>RLomelino@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Andre Goy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arcania Garcia</last_name>
      <phone>212-746-2062</phone>
      <email>arg2006@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Furman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna Weissbrot</last_name>
      <phone>212-304-5558</phone>
      <email>hw2432@mail.cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole Lamanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Arielle Baim</last_name>
      <phone>414-805-8745</phone>
      <email>abaim@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ehab Atallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica Grosse-Segerath</last_name>
      <phone>+4922147897049</phone>
      <email>jessica.grosse-segerath@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Michael Hallek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Astrid Peck</last_name>
      <phone>+49 7171 7011302</phone>
      <email>Astrid.Peck@stauferklinikum.de</email>
    </contact>
    <investigator>
      <last_name>Holger Hebart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruth Dunkel</last_name>
      <phone>+49 931 201 40958</phone>
      <email>dunkel_r@medizin.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Maria-Elisabeth Goebeler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyra Callinan</last_name>
      <phone>+353141037848</phone>
      <email>kcallinan@stjames.ie</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Vandenberghe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Nunzia Orsino</last_name>
      <phone>+390226433919</phone>
      <email>orsino.nunzia@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Ghia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.S.O. Molinette S. Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ezio Tripoli</last_name>
      <phone>+3901163361074565</phone>
      <email>ezio87.tripoli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Massimo Massaia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Bishop</last_name>
      <phone>+441202726127</phone>
      <email>catherine.bishop@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Helen McCarthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Tracey Wellman</last_name>
      <phone>+44(0)151 706 4889</phone>
      <email>Tracey.Wellman@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Pettitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Louise Enfield</last_name>
      <phone>(+)440 208 869 5088</phone>
      <email>louise.enfield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Nicki Panoskaltsis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Leonora Conneely</last_name>
      <phone>+44 208 661 3018</phone>
      <email>leonora.conneely@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Dearden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Anya Beden</last_name>
      <phone>+44 113 26 8513</phone>
      <email>ayna.beden@leedsth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Abraham Varghese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Christos Paliompeis</last_name>
      <phone>+44 208 383 4715</phone>
      <email>c.paliompeis@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Donald MacDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Royal University Hospital</name>
      <address>
        <city>Orpington</city>
        <zip>BR6 8ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Bridget Kabagambe</last_name>
      <phone>+44 168 986 3386</phone>
      <email>bridget.kabagambe@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Corinne De Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Haematology, University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie Gwilt</last_name>
      <phone>+44 238 079 4202</phone>
      <email>j.gwilt@southampton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Duncombe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
